CL2007002876A1 - Compuesto peptidico peguilado; compuesto intermediario; composicion que comprende dicho compuesto; metodo de induccion de formacion osea en un mamifero que comprende tratar con dicho compuesto peguilado; uso de dicho compuesto para el tratamiento de - Google Patents

Compuesto peptidico peguilado; compuesto intermediario; composicion que comprende dicho compuesto; metodo de induccion de formacion osea en un mamifero que comprende tratar con dicho compuesto peguilado; uso de dicho compuesto para el tratamiento de

Info

Publication number
CL2007002876A1
CL2007002876A1 CL200702876A CL2007002876A CL2007002876A1 CL 2007002876 A1 CL2007002876 A1 CL 2007002876A1 CL 200702876 A CL200702876 A CL 200702876A CL 2007002876 A CL2007002876 A CL 2007002876A CL 2007002876 A1 CL2007002876 A1 CL 2007002876A1
Authority
CL
Chile
Prior art keywords
compound
peguiled
mammer
osea
treatment
Prior art date
Application number
CL200702876A
Other languages
English (en)
Inventor
Lea Brown-Augsburger Patricia
Original Assignee
Eli Lilly And Company Soc Orga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company Soc Orga filed Critical Eli Lilly And Company Soc Orga
Publication of CL2007002876A1 publication Critical patent/CL2007002876A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL200702876A 2006-10-13 2007-10-05 Compuesto peptidico peguilado; compuesto intermediario; composicion que comprende dicho compuesto; metodo de induccion de formacion osea en un mamifero que comprende tratar con dicho compuesto peguilado; uso de dicho compuesto para el tratamiento de CL2007002876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82938306P 2006-10-13 2006-10-13

Publications (1)

Publication Number Publication Date
CL2007002876A1 true CL2007002876A1 (es) 2008-06-06

Family

ID=38974655

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702876A CL2007002876A1 (es) 2006-10-13 2007-10-05 Compuesto peptidico peguilado; compuesto intermediario; composicion que comprende dicho compuesto; metodo de induccion de formacion osea en un mamifero que comprende tratar con dicho compuesto peguilado; uso de dicho compuesto para el tratamiento de

Country Status (12)

Country Link
AR (1) AR063251A1 (es)
CL (1) CL2007002876A1 (es)
CO (1) CO6190624A2 (es)
CR (1) CR10681A (es)
CY (1) CY1110701T1 (es)
DE (1) DE602007006839D1 (es)
ES (1) ES2343917T3 (es)
MA (1) MA30873B1 (es)
PE (1) PE20080981A1 (es)
PT (1) PT2084183E (es)
TW (1) TW200817439A (es)
ZA (1) ZA200901853B (es)

Also Published As

Publication number Publication date
AR063251A1 (es) 2009-01-14
CR10681A (es) 2009-07-13
DE602007006839D1 (de) 2010-07-08
PE20080981A1 (es) 2008-07-19
MA30873B1 (fr) 2009-11-02
TW200817439A (en) 2008-04-16
CO6190624A2 (es) 2010-08-19
ZA200901853B (en) 2010-05-26
CY1110701T1 (el) 2015-06-10
PT2084183E (pt) 2010-07-16
ES2343917T3 (es) 2010-08-12

Similar Documents

Publication Publication Date Title
BRPI0913129A2 (pt) método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
BRPI0716354A2 (pt) "composiÇço e mÉtodo"
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
IL196465A0 (en) Compositions and methods for the treatment of mucositis
SI2520295T1 (sl) Postopki za preprečevanje in zdravljenje mukozitisa
PL387008A1 (pl) Sposób oczyszczania triorganofosforynów przez obróbkę dodatkiem zasadowym
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
BRPI0818544A2 (pt) Processo para tratamento de uma combinação contendo organossilano, composição e uso de uma resina orgânica.
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
MX2012004118A (es) Metodos para prevenir o tratar sarcopenia y atrofia muscular en animales.
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
ATE465229T1 (de) Textilbehandlungsverfahren und zusammensetzung
EP2049140A4 (en) KIT AND METHOD FOR TREATING THE BELTS
BRPI0909885A2 (pt) composição decorativa e método para sua utilização
EP2037941A4 (en) COBALAMINE COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF MUCOSITIS
TWI372576B (en) Organic light-emitting device and method for forming the same
IL207988A0 (en) Semiconductor surface treating agent composition and method for treating semiconductor surface using the semiconductor surface treating agent composition
BRPI0819931A2 (pt) Composições tópicas que compreendem aminoácidos não-proteogênicos e métodos de tratamento de pele
DE602006010196D1 (de) Zementzusammensetzungen mit umweltverträglichen entschäumern und verwendungsverfahren
CL2013002903A1 (es) Composicion que comprende azadiractina; metodo para el tratamiento anti-macroincrustacion de al menos un polimeros; y su uso.
GB0604471D0 (en) Device and method for the treatment of tumours
CL2008000093A1 (es) Compuestos derivados de piridina, inhibidores de p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de un desorden de agregacion plaquetaria.
PT2340328T (pt) Sistema e método para o tratamento do amianto